The clinical course of 10 liver transplant recipients who had hepatitis B virus (HBV) and five recipients with HBV and D (delta) infection before transplantation is described. Six patients who underwent eight transplants died. The estimated one and two year survival rates in patients with HBV only before transplantation were 74% and 67% respectively. The estimated one and two year survival in patients with HBV and HDV infection beforehand was 100%. Graft infection by HBV occurred in 8 of 10 patients infected with HBV only; and in 4 of 5 patients with previous HBV and HDV infection. There was a widely variable time from transplantation to the appearance of HBV markers in liver or serum, ranging from 6-331 days. Hepatitis D antigen (HDAg) appeared in three grafts very rapidly after transplantation at 4, 8, and 37 days respectively. Graft infection by HBV was accompanied by significant liver injury in six allografts in five recipients. In
Abstract
The clinical course of 10 liver transplant recipients who had hepatitis B virus (HBV) and five recipients with HBV and D (delta) infection before transplantation is described. Six patients who underwent eight transplants died. The estimated one and two year survival rates in patients with HBV only before transplantation were 74% and 67% respectively. The estimated one and two year survival in patients with HBV and HDV infection beforehand was 100%. Graft infection by HBV occurred in 8 of 10 patients infected with HBV only; and in 4 of 5 patients with previous HBV and HDV infection. There was a widely variable time from transplantation to the appearance of HBV markers in liver or serum, ranging from days. Hepatitis D antigen (HDAg) appeared in three grafts very rapidly after transplantation at 4, 8, and 37 days respectively. Graft infection by HBV was accompanied by significant liver injury in six allografts in five recipients. In particular, there was a striking morphological appearance in five infected livers in which the hepatocytes became progressively enlarged and distorted as they accumulated huge amounts of hepatitis B surface and core antigens (HBsAg, HBcAg). These features were accompanied by pericellular fibrosis and cholestasis but little associated inflammation. This syndrome carried a poor prognosis. A gradual progression to cirrhosis occurred in one additional liver. Finally, recurrent HBV infection was a principal or a contributing factor in all deaths. The presence of HBcAg and inflammation in the native liver increased the risk of HBV induced tissue damage in the graft whereas HDV infection in the host liver seemed to reduce the risk of significant HBV induced tissue damage in the allograft. These data suggest that post transplant HBV infection is accompanied by a variety of changes in the liver allograft, some of which are unique to the transplanted liver and may result in impaired allograft function.
(Gut 1992; 33: [1390] [1391] [1392] [1393] [1394] [1395] [1396] While liver transplantation has become the treatment of choice in the developed world 
Results
The 15 patients studied are described in Table I (Fig IA) . HBcAg was usually the first viral antigen to be detected by immunohistochemistry (Fig IB) . Next, the hepatocytes became considerably enlarged and contained the typical HBV type ground-glass inclusions. The inclusions were cytoplasmic, eccentric to and sometimes partly surrounding the nucleus, and were composed of finely granular pale material which seemed to retract from the cell membrane, leaving a partial clear zone between membrane and inclusion.
Immunohistochemistry showed that these distorted hepatocytes stained intensely for cytoplasmic HBsAg and cytoplasmic and nuclear HBcAg (Fig 2A, B) . Intracellular and canalicular cholestasis, as well as periportal ductular proliferation always accompanied these cellular changes as the disease progressed. Despite the striking lobular disorganisation and prominent hepatocellular changes, there was only mild inflammation. Fibrosis was variable, ranging from subtle, thin periportal and perisinusoidal collagen fibres to diffuse periportal and panlobular pericellular fibrosis (Fig 3) . In two cases there were foci of confluent lobular necrosis and haemorrhage, presumably because of superimposed ischaemia. All HBV in the grafted liver is very frequent.'-' [11] [12] [13] [14] Our experience in a smaller series is almost identical, in that HBV infection occurred in 13 of 16 grafts and death occurred in 5 of 10 patients whose grafts were infected with HBV alone.
Our data show that recurrent HBV infection is accompanied by a variety of disease patterns in the transplanted liver. One form, which seems unique to the infected allograft, was seen in four of our patients. Severe rapidly progressive liver disease was associated with the following histopathological features: distorted ground glass hepatocytes laden with HBsAg and HBcAg, cholestasis, a variable degree of fibrosis, and in some cases, lobular necrosis. This pattern is indistinguishable from 'fibrosing cholestatic hepatitis' described by Davies et al, and like them we found it to portend a bad prognosis.4 The Pittsburgh group also described a similar constellation of findings and noted that HBV infection seems to progress more rapidly when it recurs in a second allograft.2 3 This was also our experience in one patient in whom 'fibrosing cholestatic hepatitis' was seen in the first transplant at 20 weeks and progressed to require retransplantation at 32 weeks. Thereafter, a similar histological pattern evolved rapidly in the second allograft from which biopsy specimens were taken at 14, 26, and 32 days. This patient died of liver failure 2 X months after the second operation.
We observed a gradual progression to cirrhosis in one HBV infected allograft. The 
